Clinical trial · Interventional
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
NCT02763254CI-TRIAL-00037802CIVICterminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient recruitment rate
Summary
Brief summary (as posted)
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Post-transplant Lymphoproliferative Disorder | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| baltaleucel-T | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- baltaleucel-T
- description
- Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
- interventionNames
- Biological: baltaleucel-T
Primary outcomes (1)
- measure
- Best Overall Response
- timeFrame
- 1 year
- description
- Best single observed response, complete response (CR) or partial response (PR) per Lugano 2014 Disease Response Criteria, during 12 month follow-up.
Secondary outcomes (1)
- measure
- Adverse Events
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: 1. The study will include three primary cohorts, with any of the following EBV+ diseases: Cohort A - DLBCL, 1) in first or subsequent relapse, not eligible for autologous transplantation following salvage therapy OR 2) relapse following autologous transplantation. Cohort B - HL, brentuximab vedotin (BV) treatment failure or unable to tolerate BV. Cohort C - PTLD, rituximab treatment failure. 2. Presence of active lymphoma or active PTLD, based on imaging performed within the previous 3 months. 3. Tumor positive for EBV encoded RNA (EBER) based on report from certified laboratory. 4. Absolute lymphocyte count (ALC) \>500/µL 5. Male or female ≥ 12 years of age 6. Weight ≥ 35 kg 7. Eastern Cooperative Oncology Group (ECOG) performance score 0-2, inclusively or Lansky score ≥ 60, as age appropriate 8. Able to understand and comply with the requirements of the study and to provide written informed consent or age appropriate assent for pediatric patients. Exclusion Criteria: 1. Known central nervous system (CNS) lymphoma 2. Primary refractory HL or DLBCL 3. Bulky disease 4. Relapse or progression following previous autologous EBV specific T cell treatment. 5. Use of systemic corticosteroids \> 0.5 mg/kg/day prednisolone or equivalent does of alternative corticosteroid within 10 days prior to obtaining 200 mL starting material 6. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV). 7. Patient is pregnant or lactating 8. Systemic fungal, bacterial, viral or other infection that is not controlled 9. Prior allogeneic hematopoietic stem cell transplantation (allo HSCT) 10. Known history of primary immunodeficiency
References
Publications (0)
Data not yet available
No reference posted for this study.